Intel 471 Releases Report to Help Europe’s Critical Entities Navigate the Network and Information Security Directive (NIS2)
5.11.2024 10:00:00 EET | Business Wire | Press release
Today, Intel 471, a global leader in cyber threat intelligence (CTI) and intelligence-driven solutions, released its new report, NIS2 Operationalising Cyber Threat Intelligence for Critical Infrastructure Resiliency.The report offers key insights into how actionable CTI can help organisations navigate Europe’s new cybersecurity regulations, proactively mitigate digital risk, improve cyber resilience, and avoid penalties and fines.
National laws implementing the European Union’s NIS2 Directive (EU) 2022/2555 to lift the cyber resilience of critical infrastructure across Europe went into effect on 18 October 2024. NIS2 has dramatic implications for how important and essential operators of critical services manage cyber risks compared to its predecessor, NIS1, the 2016 Network and Information Systems Directive. It gives regulators wider supervisory powers, introduces higher standards for cyber risk management, mandatory incident reporting and tougher sanctions. If not followed, essential entities face administrative fines of up to €10 million, or 2% of annual global turnover, whichever is higher. This directive is a major shift in cyber risk management and supply chain security for entities operating energy, transport, banking, health, water, digital infrastructure, managed IT services, public administration and many more subsectors.
In this report, Intel 471 outlines how these entities in critical sectors affected by the European Commission’s NIS2 Directive can leverage premier CTI and intelligence-driven threat hunting to proactively mitigate digital threats and meet the directive’s higher risk management and incident reporting requirements. The report provides organizations with best practices to reduce cyber risk, anticipate threats, prioritise remediation of cloud resources and other IT assets, and continuously improve risk management measures to boost resilience and recovery.
“It is the right time to adopt NIS2 given today’s high stakes cybersecurity threat landscape. We’re seeing nation-state and cybercrime activity increasingly overlap, often driven by geopolitical events that create higher risks to all critical sectors in Europe. Defenders are overwhelmed by data and need timely intelligence that helps them focus on emerging threats, adversary tactics, and vulnerabilities that pose the greatest risk to them,” says Michael DeBolt, Chief Intelligence Officer at Intel 471. “Our unmatched human intelligence capability, patented malware emulation and tracking insights, and human-validated automated collection across thousands of threat actor communities help our customers in critical sectors across the globe understand their exposure and proactively mitigate digital risks. We go a step further by providing carefully curated intelligence-driven threat hunting content to rapidly identify and stop advanced threats in their tracks.”
Organisations impacted by NIS2 can utilise Intel 471’s unique CTI capabilities to improve security posture, reduce their attack surface and enhance resilience. “Being prepared with timely and trusted intelligence and threat hunting content that identifies adversarial techniques missed by traditional detection methods is critical for organisations to gain early visibility of emerging threats and proactively respond to cyber incidents. This intelligence-led approach to cyber defense and third party risk is at the heart of NIS2 directive,” says DeBolt.
NIS2’s broader scope than NIS1 dictates that many affected entities are urgently working to mature their CTI programs to better support their NIS2 cyber risk management strategies. The CTI Capability Maturity Model (CTI-CMM) — a free and vendor-neutral, “stakeholder-first” model, sponsored by Intel 471 and 27 other CTI industry expert peers from across the globe, assists organisations in building successful, impactful CTI programs.
For more details and to download the Intel 471 report, please visit: NIS2 Operationalising Cyber Threat Intelligence for Critical Infrastructure Resilience
About Intel 471
Intel 471 empowers enterprises, government agencies, and other organizations to win the cybersecurity war using the real-time insights about adversaries, their relationships, threat patterns, and imminent attacks relevant to their businesses. The company’s platform collects, interprets, structures, and validates human-led, automation-enhanced intelligence, which fuels our external attack surface and advanced behavioral threat hunting solutions. Customers utilize this operationalized intelligence to drive a proactive response to neutralize threats and mitigate risk. Organizations across the globe leverage Intel 471’s world-class intelligence, our trusted practitioner engagement and enablement, and globally dispersed ground expertise as their frontline guardian against the ever-evolving landscape of cyber threats to fight the adversary — and win. Learn more at www.intel471.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241105566758/en/
Contacts
Erica Stuchel
Intel471@w2comm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom